December 9, 2016 / 3:49 PM / 7 months ago

BRIEF-Bioinvent terminates BI-505 phase II study

1 Min Read

Dec 9 (Reuters) - Bioinvent

* Bioinvent terminates current BI-505 phase II study

* Says decision follows bioinvent's review and discussion with U.S. Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below